Claims for Patent: 10,232,000

Summary for Patent: 10,232,000

Title:	Stem cells derived from basal portion of chorionic trophoblast layer and cell therapy comprising same
Abstract:	The present disclosure relates to stem cells derived from the basal portion of the chorionic trophoblast layer (bCT), which is a part of the issues of the placenta, and cell therapy comprising same. Stem cells derived from the basal portion of the chorionic trophoblast layer according to the present invention exhibit uniform growth characteristic, and superb proliferation and differentiation characteristic as compared with the conventional stem cells derived from the full placenta or other tissues, and exhibit excellent tissue regeneration effect in an animal model, thus can be effectively used in cell therapy.
Inventor(s):	Ha; Chul Won (Seoul, KR), Kim; Jin A. (Gyeonggi-do, KR)
Assignee:	Samsung Life Public Welfare Foundation (Seoul, KR)
Application Number:	15/110,668
Patent Claims:	1. A method for regenerating tissues of a subject in need thereof, comprising transplanting a composition to the subject, wherein the composition comprises stem cells derived from a basal portion of a chorionic trophoblast layer (bCT) which is a part of the tissues of the placenta or cells differentiated from the stem cells as an active ingredient; wherein the stem cells derived from the bCT are prepared by the following steps: (a) isolating a chorionic trophoblast layer which is a part of the tissues of the placenta, from placenta; (b) preparing the bCT which is derived from a tissue corresponding to a thickness of 20 to 30% as a portion adjacent to a chorionic membrane of a total chorionic trophoblast layer positioned between the chorionic membrane and a decidua; (c) obtaining cells derived from the bCT by treating the bCT with one or more kinds of enzymes selected from the group consisting of trypsin, collagenase, dispase, DNase, RNase, protease, lipase, hyaluronidase, and elastase; and (d) screening the stem cells from the obtained cells derived from the bCT. 2. The method of claim 1, wherein the tissue is one or more kinds selected from the group consisting of cartilage, fat, bone, nerve, ligament, and tendon. 3. The method of claim 2, wherein the cartilage is hyaline cartilage, fibrocartilage, or elastic cartilage. 4. The method of claim 2, wherein the cartilage is selected from the group consisting of articular cartilage, ear cartilage, nasal cartilage, elbow cartilage, meniscus, knee cartilage, costal cartilage, ankle cartilage, tracheal cartilage, laryngeal cartilage, and spinal cartilage. 5. A method of isolating stem cells from basal portion of a chorionic trophoblast layer (bCT) comprising the following steps: (a) isolating a chorionic trophoblast layer which is a part of the tissues of the placenta, from placenta; (b) preparing the bCT which is derived from a tissue corresponding to a thickness of 20 to 30% as a portion adjacent to a chorionic membrane of a total chorionic trophoblast layer positioned between the chorionic membrane and a decidua; (c) obtaining cells derived from the bCT by treating the bCT with one or more kinds of enzymes selected from the group consisting of trypsin, collagenase, dispase, DNase, RNase, protease, lipase, hyaluronidase, and elastase; and (d) screening the stem cells from the obtained cells derived from the bCT. 6. The method of claim 5, wherein preparing the bCT in step (b) is performed by a using sterilized forceps and a knife. 7. The method of claim 5, wherein screening the stem cells in step (d) is performed by a method comprising the following steps: (i) culturing the obtained cells derived from the bCT from step (c) in a culture container; and (ii) screening the attached cultured cells wherein the attached cultured cells are attached to the bottom of the culture container. 8. The method of claim 5, further comprising the step of transplanting the stem cells from basal portion of chorionic trophoblast layer (bCT) in a patient in need of a cellular therapeutic agent. 9. The method of claim 8, wherein the cellular therapeutic agent is used to treat a patient having cartilage damage, cartilage defect, bone defect, tendon-ligament defect, or fat tissue defect. 10. The method of claim 9, wherein the cartilage defect is selected from the group consisting of cartilage injury, cartilage tear, chondromalacia, cartilage necrosis, osteochondritis, cartilage loss, and osteoarthritis.

Details for Patent 10,232,000

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2034-01-08
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2034-01-08
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2034-01-08